依达拉奉联合醒脑静注射液辅助治疗急性脑出血临床疗效观察

The Clinical Observation of Edaravone combined with Xingnaojing Injection in the Adjuvant Therapy of Acute Cerebral Hemorrhage

目的:观察依达拉奉联合醒脑静注射液辅助治疗急性脑出血临床疗效。方法:将我院2015年3月-2016年9月收治的急性脑出血患者74例随机分为对照组和观察组各37例,对照组在常规治疗基础上辅以依拉达奉治疗,观察组在对照组基础上联合醒脑静注射液治疗,比较两组治疗前后NIHSS评分及IL-1、TNF-α、IL-6水平。结果:两组治疗后NIHSS评分均较治疗前明显降低(P<0.05),但观察组降低幅度明显优于对照组(P<0.05);两组治疗后IL-1、TNF-α、Il-6水平均明显下降,且观察组下降幅度较对照组明显(P<0.05)。结论:依达拉奉联合醒脑静注射液辅助治疗急性脑出血可有效促使患者神经功能恢复及炎性因子水平下降,建议临床应用。

Objective:To explore the clinical efficacy of Edaravone combined with Xingnaojing injection in the adjuvant therapy of acute cerebral hemorrhage. Methods:74 patients with acute cerebral hemorrhage admitted in our hospital from Mar 2015 to Sept 2016 were randomly divided into control group and observation group,each group was 37 cases. The control group was treated with Edaravone based on the conventional treatment,while the observation group was treated with Xingnaojing injection based on the control group. The NIHSS score and the levels of IL-1,TNF-α,IL-6 were compared between the two groups before and after the treatment. Results:Compared with the before treatment,the NIHSS scores in the two groups were significantly lower(P<0.05),but the amplitude in the observation group was better than that in the control group(P<0.05).The levels of IL-1,TNF-α and IL-6 in the two groups decreased significantly after treatment,and the decrease in the observation group was larger than that in the control group(P<0.05). Conclusion: It may effectively promote the recovery of neurological function and decrease the level of inflammatory factors that patient with acute cerebral hemorrhage adjuvant treated by combination of Edaravone and Xingnaojing injection,and it is worthy of clinical application.